---
title: "HUMA.US (HUMA.US) — Related News"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/HUMA.US/news.md"
symbol: "HUMA.US"
name: "HUMA.US"
parent: "https://longbridge.com/en/quote/HUMA.US.md"
datetime: "2026-06-13T19:49:06.233Z"
locales:
  - [en](https://longbridge.com/en/quote/HUMA.US/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/HUMA.US/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/HUMA.US/news.md)
---

# HUMA.US (HUMA.US) — Related News

### [Humacyte Enters Underwriting Agreement for 47.6M-Share Offering at $1.05, Nets ~$46.8M](https://longbridge.com/en/news/289513555.md)
*2026-06-11T20:53:01.000Z*
> Humacyte entered an underwriting agreement to sell 47.6 million shares at $1.05 each, raising approximately $46.8 millio

### [Why Is Humacyte Stock Falling Thursday?](https://longbridge.com/en/news/289488162.md)
*2026-06-11T15:21:22.000Z*
> Humacyte (HUMA) stock fell 22% despite positive Phase 3 trial data for its ATEV product, which met primary endpoints wit

### [12 Health Care Stocks Moving In Thursday's Pre-Market Session](https://longbridge.com/en/news/289464411.md)
*2026-06-11T12:05:51.000Z*
> In Thursday's pre-market session, several healthcare stocks showed significant volatility. Gainers included Propanc Biop

### [At a glance: Stocks gapping down premarket](https://longbridge.com/en/news/289456506.md)
*2026-06-11T11:27:38.000Z*
> Several stocks, including Humacyte (-17.9%), PureCycle Technologies (-14.5%), Oracle (-7.2%), and Oxford Industries (-6.

### [Humacyte, Inc. Announces Pricing of Public Offering of Common Stock | HUMA Stock News](https://longbridge.com/en/news/289393549.md)
*2026-06-10T17:08:00.000Z*
> Humacyte, Inc. (Nasdaq: HUMA) announced the pricing of an underwritten public offering of 47,619,048 shares of common st

### [Humacyte's Bioengineered Blood Vessel Hits Primary Endpoint in Phase 3 Trial](https://longbridge.com/en/news/289379825.md)
*2026-06-10T21:25:34.000Z*
> Humacyte's bioengineered blood vessel met its primary endpoint in a Phase 3 trial for dialysis access, showing 91 more c